COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04056481
Expanded Access Status : Available
First Posted : August 14, 2019
Last Update Posted : January 13, 2021
Sponsor:
Information provided by (Responsible Party):
Alnylam Pharmaceuticals

Brief Summary:
The purpose of this study is to provide expanded access of givosiran to patients with Acute Hepatic Porphyria (AHP).

Condition or disease Intervention/treatment
Acute Hepatic Porphyria Drug: Givosiran

Detailed Description:
Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact the study research staff using the Contacts provided. For general information, see the link provided in More Information.

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Treatment IND/Protocol
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria (AHP)



Intervention Details:
  • Drug: Givosiran
    givosiran (ALN-AS1) administered as a subcutaneous (SC) injection
    Other Name: ALN-AS1

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Diagnosed with Acute Hepatic Porphyria (Acute Intermittent Porphyria, Hereditary Coproporhyria, Variegate Porphyria, ALA dehydratase deficient porphyria)
  • Have adequate venous access for program sample collections as judged by the Investigator for study sample collections

Exclusion Criteria:

  • Previously or currently participating in a givosiran clinical trial
  • Has any of the following laboratory parameter assessments at Screening:

    1. Alanine aminotransferase (ALT) >2×ULN
    2. Total bilirubin >1.5×ULN. Patients with elevated total bilirubin that is secondary to documented Gilbert's syndrome are eligible if the total bilirubin is <2×ULN
    3. Estimated Glomerular Filtration Rate (eGFR) <15 mL/min/1.73 m2
  • On an active liver transplantation waiting list

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04056481


Contacts
Layout table for location contacts
Contact: Alnylam EAP Hotline 1-877-256-9526 eap@alnylam.com

Locations
Layout table for location information
Australia
Program Site Available
Melbourne, Australia
Program Site Available
Richmond, Australia
Program Site Available
Wyong, Australia
Belgium
Program Site Available
Brussels, Belgium
Program Site Available
Leuven, Belgium
Program Site Available
Liège, Belgium
Luxembourg
Program Site Available
Luxembourg City, Luxembourg
Netherlands
Program Site Available
Rotterdam, Netherlands
Spain
Program Site Available
Barcelona, Spain
Program Site Available
Cieza, Spain
Program Site Available
Madrid, Spain
Program Site Available
Palma De Mallorca, Spain
Program Site Available
Pamplona, Spain
Program Site Available
Sabadell, Spain
Program Site Available
Sevilla, Spain
Sweden
Program Site Available
Stockholm, Sweden
Sponsors and Collaborators
Alnylam Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Medical Director Alnylam Pharmaceuticals
Additional Information:
Layout table for additonal information
Responsible Party: Alnylam Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04056481    
Other Study ID Numbers: ALN-AS1-005
First Posted: August 14, 2019    Key Record Dates
Last Update Posted: January 13, 2021
Last Verified: January 2021
Keywords provided by Alnylam Pharmaceuticals:
Acute Hepatic Porphyria (AHP)
Acute Intermittent Porphyria (AIP)
Porphyria
Acute Intermittent
Acute Porphyria
Hereditary Coproporphyria (HCP)
Variegate Porphyria (VP)
ALA Dehydratase Deficient Porphyria (ADP)
Givosiran
Expanded Access
EAP
Additional relevant MeSH terms:
Layout table for MeSH terms
Porphyrias, Hepatic
Coproporphyria, Hereditary
Porphyria, Erythropoietic
Porphyrias
Metabolic Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Liver Diseases
Digestive System Diseases